Literature DB >> 20147901

Microtubules and resistance to tubulin-binding agents.

Maria Kavallaris1.   

Abstract

Microtubules are dynamic structures composed of alpha-beta-tubulin heterodimers that are essential in cell division and are important targets for cancer drugs. Mutations in beta-tubulin that affect microtubule polymer mass and/or drug binding are associated with resistance to tubulin-binding agents such as paclitaxel. The aberrant expression of specific beta-tubulin isotypes, in particular betaIII-tubulin, or of microtubule-regulating proteins is important clinically in tumour aggressiveness and resistance to chemotherapy. In addition, changes in actin regulation can also mediate resistance to tubulin-binding agents. Understanding the molecular mechanisms that mediate resistance to tubulin-binding agents will be vital to improve the efficacy of these agents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20147901     DOI: 10.1038/nrc2803

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  115 in total

1.  Cell cycle-dependent changes in microtubule dynamics in living cells expressing green fluorescent protein-alpha tubulin.

Authors:  N M Rusan; C J Fagerstrom; A M Yvon; P Wadsworth
Journal:  Mol Biol Cell       Date:  2001-04       Impact factor: 4.138

2.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.

Authors:  M Kavallaris; D Y Kuo; C A Burkhart; D L Regl; M D Norris; M Haber; S B Horwitz
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 3.  The importance of p53 location: nuclear or cytoplasmic zip code?

Authors:  Aurora O'Brate; Paraskevi Giannakakou
Journal:  Drug Resist Updat       Date:  2003-12       Impact factor: 18.500

Review 4.  Microtubules: a dynamic target in cancer therapy.

Authors:  Eddy Pasquier; Maria Kavallaris
Journal:  IUBMB Life       Date:  2008-03       Impact factor: 3.885

Review 5.  Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.

Authors:  Edith A Perez
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

Review 6.  The tubulin code.

Authors:  Kristen J Verhey; Jacek Gaertig
Journal:  Cell Cycle       Date:  2007-06-26       Impact factor: 4.534

Review 7.  Drug resistance mechanisms in cancer cells: a proteomics perspective.

Authors:  Nicole M Verrills; Maria Kavallaris
Journal:  Curr Opin Mol Ther       Date:  2003-06

8.  Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin.

Authors:  Lucia Cicchillitti; Roberta Penci; Michela Di Michele; Flavia Filippetti; Domenico Rotilio; Maria Benedetta Donati; Giovanni Scambia; Cristiano Ferlini
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

9.  Taxol stabilizes microtubules in mouse fibroblast cells.

Authors:  P B Schiff; S B Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

10.  Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.

Authors:  Johan Vansteenkiste; Primo N Lara; Thierry Le Chevalier; Jean-Luc Breton; Philip Bonomi; Alan B Sandler; Mark A Socinski; Catherine Delbaldo; Brent McHenry; David Lebwohl; Ronald Peck; Martin J Edelman; Mark Edelman
Journal:  J Clin Oncol       Date:  2007-07-02       Impact factor: 44.544

View more
  345 in total

Review 1.  Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain.

Authors:  Marco Sisignano; Ralf Baron; Klaus Scholich; Gerd Geisslinger
Journal:  Nat Rev Neurol       Date:  2014-11-04       Impact factor: 42.937

2.  Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site.

Authors:  R M Hartley; J Peng; G A Fest; S Dakshanamurthy; D E Frantz; M L Brown; S L Mooberry
Journal:  Mol Pharmacol       Date:  2011-12-14       Impact factor: 4.436

Review 3.  Weekly paclitaxel in the treatment of recurrent ovarian cancer.

Authors:  Richard D Baird; David S P Tan; Stan B Kaye
Journal:  Nat Rev Clin Oncol       Date:  2010-08-03       Impact factor: 66.675

4.  Trojan-horse nanotube on-command intracellular drug delivery.

Authors:  Chia-Hsuan Wu; Cong Cao; Jin Ho Kim; Chih-Hsun Hsu; Harold J Wanebo; Wayne D Bowen; Jimmy Xu; John Marshall
Journal:  Nano Lett       Date:  2012-10-25       Impact factor: 11.189

5.  Eg5 inhibitor, a novel potent targeted therapy, induces cell apoptosis in renal cell carcinoma.

Authors:  Sentai Ding; Zuohui Zhao; Dingqi Sun; Fei Wu; Dongbin Bi; Jiaju Lu; Naidong Xing; Liang Sun; Haihu Wu; Kejia Ding
Journal:  Tumour Biol       Date:  2014-05-07

6.  Characterization of a human βV-tubulin antibody and expression of this isotype in normal and malignant human tissue.

Authors:  Suzan K Chao; Yihong Wang; Pascal Verdier-Pinard; Chia-Ping H Yang; Lingling Liu; Alicia Rodriguez-Gabin; Hayley M McDaid; Susan Band Horwitz
Journal:  Cytoskeleton (Hoboken)       Date:  2012-07-02

7.  Taccalonolide binding to tubulin imparts microtubule stability and potent in vivo activity.

Authors:  A L Risinger; J Li; M J Bennett; C C Rohena; J Peng; D C Schriemer; S L Mooberry
Journal:  Cancer Res       Date:  2013-09-18       Impact factor: 12.701

Review 8.  The role of Plk3 in oncogenesis.

Authors:  C Helmke; S Becker; K Strebhardt
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

9.  A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines.

Authors:  Yi Shi; Lin Sun; Ge Chen; Dongyan Zheng; Li Li; Wanguo Wei
Journal:  Target Oncol       Date:  2015-04-29       Impact factor: 4.493

10.  Cys34-PEGylated Human Serum Albumin for Drug Binding and Delivery.

Authors:  Jonathan G Mehtala; Chris Kulczar; Monika Lavan; Gregory Knipp; Alexander Wei
Journal:  Bioconjug Chem       Date:  2015-05-08       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.